Definium Therapeutics
The Associate Director, Drug Product Development leads outsourced drug product development and manufacturing activities across early and late phases, serving as the primary technical contact for CDMO partners. This role oversees process development, technology transfer, scale‑up, validation, and secondary packaging development, ensuring alignment with program timelines and regulatory expectations.
Headquarters
New York, New York, United States
Company Size
1-10 employees
Founded
2019
Definium Therapeutics (formerly MindMed) is a clinical-stage biopharmaceutical company harnessing the therapeutic potential of psychedelic medicine to develop treatments for psychiatric conditions including generalized anxiety disorder, major depressive disorder, and autism spectrum disorder. Its lead programs include DT120 ODT, a proprietary formulation of lysergide (LSD) D-tartrate, and DT402, the R-enantiomer of MDMA targeting core symptoms of autism spectrum disorder. The company is guided by precision science and evidence-based development to redefine mental healthcare.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Definium Therapeutics.
14% below the average for this role
Director, Technical Operations Drug Product
Cytokinetics
Director, Drug Product Development
BioCryst Pharmaceuticals
Principal Scientist I, Biologics Drug Product Development
AbbVie
Director, Drug Product Development
Iambic Therapeutics
Head of Drug Product Development
Ironwood Pharmaceuticals
Senior Formulation Scientist (Drug Product)
Eurofins